Simard et al., 20101212 Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. 2010;62:3776-82.
|
Stockholm/Sweden |
Retrospective analytical observational cohort/control group study with comparators of the general population for each case |
9027 |
To determine the risk of cancer in patients with JIA versus the general population. |
JIA |
Up to 16 years old |
- |
RR for cancer in all numbers: 1.1 (CI 0.9-1.5); RR for MLD in JIA after 1987: 4.2 (CI 1.7-10.7); RR for general cancer in JIA after 1987: 2.3 (CI 1.2-4.4). |
Cancer in general, MLD |
High risk in patients with a less than 20 years JIA Dx; it may be associated with current therapies. |
Horneff, 20101313 Horneff G. Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Z Rheumatol. 2010;69:516-26.
|
Sankt Augustin/Germany [German language study] |
Case report |
5 |
Report of 5 cases documented in the German register of cancer in patients with JIA treated with TNF-α inhibitor agents. |
JIA |
Up to 16 years old |
MTX; TNF blockers (etanercept; adalimumab; infliximab) |
- |
NHL; HL; thyroid cancer; yolk sac cancer; cervical dysplasia |
Consider and report risks and benefits of using biological agents; long-term observation of patients. |
Bernatsky et al., 20111515 Bernatsky S, Rosenberg AM, Oen KG, Duffy CM, Ramsey-Goldman R, Labrecque J, et al. Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol. 2011;38:760-3.
|
Montreal, Quebec/Canada |
Retrospective analytical observational cohort/control group study with comparators of the general population for each case |
1834 |
To present preliminary data on the incidence of malignancy in JIA, compared with the rates in the general population. |
JIA |
Mean of 8.6 years (standard deviation, 5.1) |
- |
SIR for cancer in general: 0.12 (CI 0.0-0.70); SIR for hematologic cancer: 0.76 (CI 0.02-4.21) |
HL |
Soon after a Dx of JIA, the overall risk of cancer is not increased; it is possible an increased risk of MLD. |
Horneff et al., 20111414 Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology. 2011;50:2306.
|
Sankt Augustin/Germany |
Observational analytical retrospective cohort study |
1260 |
To review German registers of cancer in children exposed to TNF blockers and verify if there is a higher risk, especially for lymphoma. |
JIA |
Up to 16 years old |
MTX; TNF blockers (etanercept; adalimumab; infliximab) |
- |
NHL; HL; thyroid carcinoma; yolk sac carcinoma; cervical dysplasia |
Patients with JIA exposed to biological agents or cytotoxic drugs should have a long-term follow-up, even in adulthood. |
Nordstrom et al., 20121717 Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012;64:1357-64.
|
Lexington, Massachusetts/USA |
Retrospective analytical observational cohort/control group study with 20 comparators of the general population for each case |
3605 |
To estimate the relative risk of diagnosis of cancer among patients with JIA, compared with patients without JIA. |
JIA |
Mean of 11 years |
- |
HR: 2.8 (CI 0.9-8.3); SIR for JIA cohort: 4.0 (CI 2.6-6.0); SIR for non-JIA cohort: 1.4 (CI 0.6-2.6) |
Lymphoma; soft tissue cancer |
A significant risk of cancer (nearly 3 times greater) was found in patients with JIA not treated with biological agents. |
Beukelman et al., 20121818 Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:1263-71.
|
Alabama/USA |
Observational analytical retrospective cohort/controlled study with two cohorts of children with Dx of chronic disease without JIA |
7812 |
To determine the incidence of malignancy related to the treatment of children with JIA, compared with children without JIA. |
JIA |
Up to 16 years old |
MTX; TNF blockers |
SIR for cancer in general: 4.4 (CI 1.8-9.0); SIR for biological agents: 6.9 (CI 2.3-16); SIR for MTX: 3.9 (CI 0.4-14); SIR for TNF blockers: 0,0 (CI 0-9.7) |
Brain cancer; leukemia; soft tissue cancer; GIT cancer |
The cancer risk seems to be higher in children with JIA, but it is not associated with the use of TNF blockers. |
Bernatsky et al., 20131616 Bernatsky S, Rosenberg AM, Oen KG, Duffy CM, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in childhood-onset & systemic lupus. Arthritis Res Ther. 2013;15:R198.
|
Montreal, Quebec/Canada |
Retrospective analytical observational cohort/control group study with comparators of the general population for each case |
1020 |
To evaluate the incidence of cancer in JSLE. |
JSLE |
Up to 18 years old; mean of 12.6 years (standard deviation, 3.6) |
- |
SIR for invasive cancer: 4.7 (CI 2.6-7.8); SIR for hematologic cancer: 5.2 (CI 1.1-15.2) |
NHL/leukemia |
There is an increased risk of cancer in JSLE that can arise only after the patient has reached adulthood. |
Hasija et al., 20141919 Hasija RP, Silverman ED, Cho S, Fung L, Benseler SM, Cameron B, et al. A170: Neoplasms in pediatric patients with rheumatic diseases exposed to biologics – a quarternary centre's experience. Arthritis Rheumatol. 2014;66(Suppl. 11):S220-1.
|
Toronto/Canada |
Observational analytical retrospective cohort study |
357 |
To determine the rate and also risk factors for the occurrence of cancer in patients with JIA treated with biological agents. |
JIA/IU/PAN |
Onset of rheumatic disease: 1.7-7.3; Dx of neoplasm; 15.3-17.9 years |
MTX; infliximab; etanercept |
- |
NPC e renal carcinoma; MLD; PMT; sarcoma |
Patients with refractory disease in use of drugs should have a routine surveillance for onset of cancer. |
Kok et al., 20142020 Kok VC, Horng JT, Huang JL, Yeh KW, Gau JJ, Chang CW, et al. Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis. BMC Cancer. 2014;14:634.
|
Linkou/Taiwan |
Retrospective analytical observational cohort/control group study with four comparators of the general population for each case |
2892 |
To investigate the magnitude of risk associated with JIA and its treatment to the development of cancer in children in Taiwan. |
JIA |
Up to 16 years old |
MTX; TNF blockers |
HR: 3.14 (CI 1.98-4.98), RR: 2.75 (CI 1.75-4.32) and IRR: 3.21 (CI 2.01-5.05) for cancer; IRR: 7.38 for leukemia, 8.3 for lymphoma, 11.07 for sarcoma, 2.08 for others. |
Leukemia; lymphoma; soft tissue sarcoma; other |
Children with JIA have a 3-time higher cancer risk East Asia; biological agents do not increase this risk. |